← Back to All US Stocks

agilon health, inc. (AGL) Stock Fundamental Analysis & AI Rating 2026

AGL NYSE Services-Misc Health & Allied Services, NEC DE CIK: 0001831097
Updated This Month • Analysis: Mar 19, 2026 • SEC Data: 2025-12-31
Combined AI Rating
STRONG SELL
92% Confidence
STRONG AGREEMENT
STRONG SELL
92% Conf
STRONG SELL
92% Conf

📊 AGL Key Takeaways

Revenue: $5.9B
Net Margin: -6.6%
Free Cash Flow: $-119.0M
Current Ratio: 1.02x
Debt/Equity: 0.28x
EPS: $0.00
AI Rating: STRONG SELL with 92% confidence
agilon health, inc. (AGL) receives a STRONG SELL rating with 92% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $5.9B, net profit margin of -6.6%, and return on equity (ROE) of -308.8%, agilon health, inc. demonstrates mixed fundamentals in the Services sector. Below is our complete AGL stock analysis for 2026.

Is agilon health, inc. (AGL) a Good Investment?

Claude

Agilon Health faces severe operational distress with persistent negative profitability and deteriorating cash flows, burning $119M in free cash flow annually while revenues declined 2.1% YoY. The company's negative net margin of -6.6% and negative operating income of $463.2M indicate fundamental business model challenges that are not self-correcting. With only $173.7M in cash against $1.1B in liabilities and negative interest coverage, the company faces material solvency concerns in the near term.

ChatGPT

agilon health’s fundamentals are weak: revenue declined, operating losses remain large, and the business is consuming cash rather than generating it. While debt is low and cash provides some near-term cushion, the combination of negative margins, negative free cash flow, and a very thin equity base points to poor financial quality and elevated balance-sheet risk if losses persist.

Why Buy agilon health, inc. Stock? AGL Key Strengths

Claude
  • + Positive debt-to-equity ratio of 0.28x suggests manageable leverage levels relative to equity base
  • + Current ratio of 1.02x indicates ability to meet short-term obligations, though tightened
  • + Maintains $173.7M cash position providing liquidity runway despite operational losses
ChatGPT
  • + Revenue scale remains substantial at $5.93B, which suggests the company still has meaningful market presence
  • + Debt levels are modest relative to equity, with only $34.99M of long-term debt and a 0.28x debt-to-equity ratio
  • + Cash of $173.71M and a current ratio of 1.02x provide limited near-term liquidity support

AGL Stock Risks: agilon health, inc. Investment Risks

Claude
  • ! Negative free cash flow of -$119M annually is unsustainable and depleting cash reserves at alarming rate
  • ! Operating losses of -$463.2M and negative operating margin of -7.8% indicate inability to generate profit from core operations
  • ! Revenue decline of 2.1% YoY combined with negative profitability suggests deteriorating competitive position in health services sector
  • ! Negative interest coverage of -360.8x indicates company cannot service debt from operating earnings
  • ! Equity base of only $126.7M against $1.3B in assets creates minimal equity cushion for creditors
ChatGPT
  • ! Profitability is deeply negative, with a -7.8% operating margin and -6.6% net margin
  • ! Cash generation is weak, with negative operating cash flow and negative free cash flow indicating the model is not self-funding
  • ! Balance-sheet resilience is thin, with only $126.73M of equity and extremely poor ROE/ROA signaling sustained value erosion

Key Metrics to Watch

Claude
  • * Operating cash flow trend - must return to positive to avoid insolvency within 18-24 months
  • * Revenue stabilization - reversal of YoY decline is prerequisite for recovery
  • * Operating margin improvement - needs to demonstrate clear path to profitability or break-even operations
  • * Cash burn rate and remaining cash runway - critical for determining survival timeline
ChatGPT
  • * Operating cash flow and free cash flow trend
  • * Operating margin improvement versus revenue growth

agilon health, inc. (AGL) Financial Metrics & Key Ratios

Revenue
$5.9B
Net Income
$-391.3M
EPS (Diluted)
$0.00
Free Cash Flow
$-119.0M
Total Assets
$1.3B
Cash Position
$173.7M

💡 AI Analyst Insight

agilon health, inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

AGL Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin -7.8%
Net Margin -6.6%
ROE -308.8%
ROA -30.8%
FCF Margin -2.0%

AGL vs Services Sector: How agilon health, inc. Compares

How agilon health, inc. compares to Services sector averages

Net Margin
AGL -6.6%
vs
Sector Avg 10.0%
AGL Sector
ROE
AGL -308.8%
vs
Sector Avg 16.0%
AGL Sector
Current Ratio
AGL 1.0x
vs
Sector Avg 1.5x
AGL Sector
Debt/Equity
AGL 0.3x
vs
Sector Avg 0.7x
AGL Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is agilon health, inc. Stock Overvalued? AGL Valuation Analysis 2026

Based on fundamental analysis, agilon health, inc. has mixed fundamental signals relative to the Services sector in 2026.

Return on Equity
-308.8%
Sector avg: 16%
Net Profit Margin
-6.6%
Sector avg: 10%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.28x
Sector avg: 0.7x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

agilon health, inc. Balance Sheet: AGL Debt, Cash & Liquidity

Current Ratio
1.02x
Quick Ratio
1.02x
Debt/Equity
0.28x
Debt/Assets
90.0%
Interest Coverage
-360.78x
Long-term Debt
$35.0M

AGL Revenue & Earnings Growth: 5-Year Financial Trend

AGL 5-year financial data: Year 2021: Revenue $1.8B, Net Income -$282.6M, EPS N/A. Year 2022: Revenue $2.7B, Net Income -$60.1M, EPS $-0.20. Year 2023: Revenue $4.3B, Net Income -$406.5M, EPS $-1.03. Year 2024: Revenue $6.1B, Net Income -$106.6M, EPS $-0.22. Year 2025: Revenue $6.1B, Net Income -$262.6M, EPS $-0.48.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: agilon health, inc.'s revenue has grown significantly by 231% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.48 indicates the company is currently unprofitable.

AGL Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-2.0%
Free cash flow / Revenue

AGL Quarterly Earnings & Performance

Quarterly financial performance data for agilon health, inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $1.4B -$110.2M $-0.27
Q2 2025 $1.4B -$30.7M $-0.07
Q1 2025 $1.5B -$6.1M $0.00
Q3 2024 $1.1B -$31.4M $-0.06
Q2 2024 $1.1B -$727.0K $-0.01
Q1 2024 $1.1B -$6.1M $0.01
Q3 2023 $694.9M -$30.7M $-0.07
Q2 2023 $670.1M -$727.0K $0.00

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

agilon health, inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$105.8M
Cash generated from operations
Capital Expenditures
$13.2M
Investment in assets
Dividends
None
No dividend program

AGL SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for agilon health, inc. (CIK: 0001831097)

📋 Recent SEC Filings

Date Form Document Action
Apr 3, 2026 4 xslF345X06/wk-form4_1775259626.xml View →
Apr 3, 2026 4 xslF345X06/wk-form4_1775259553.xml View →
Apr 3, 2026 4 xslF345X06/wk-form4_1775259503.xml View →
Apr 3, 2026 4 xslF345X06/wk-form4_1775259453.xml View →
Apr 3, 2026 4 xslF345X06/wk-form4_1775259395.xml View →

Frequently Asked Questions about AGL

What is the AI rating for AGL?

agilon health, inc. (AGL) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are AGL's key strengths?

Claude: Positive debt-to-equity ratio of 0.28x suggests manageable leverage levels relative to equity base. Current ratio of 1.02x indicates ability to meet short-term obligations, though tightened. ChatGPT: Revenue scale remains substantial at $5.93B, which suggests the company still has meaningful market presence. Debt levels are modest relative to equity, with only $34.99M of long-term debt and a 0.28x debt-to-equity ratio.

What are the risks of investing in AGL?

Claude: Negative free cash flow of -$119M annually is unsustainable and depleting cash reserves at alarming rate. Operating losses of -$463.2M and negative operating margin of -7.8% indicate inability to generate profit from core operations. ChatGPT: Profitability is deeply negative, with a -7.8% operating margin and -6.6% net margin. Cash generation is weak, with negative operating cash flow and negative free cash flow indicating the model is not self-funding.

What is AGL's revenue and growth?

agilon health, inc. reported revenue of $5.9B.

Does AGL pay dividends?

agilon health, inc. does not currently pay dividends.

Where can I find AGL SEC filings?

Official SEC filings for agilon health, inc. (CIK: 0001831097) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is AGL's EPS?

agilon health, inc. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is AGL a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, agilon health, inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is AGL stock overvalued or undervalued?

Valuation metrics for AGL: ROE of -308.8% (sector avg: 16%), net margin of -6.6% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.

Should I buy AGL stock in 2026?

Our dual AI analysis gives agilon health, inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is AGL's free cash flow?

agilon health, inc.'s operating cash flow is $-105.8M, with capital expenditures of $13.2M. FCF margin is -2.0%.

How does AGL compare to other Services stocks?

Vs Services sector averages: Net margin -6.6% (avg: 10%), ROE -308.8% (avg: 16%), current ratio 1.02 (avg: 1.5).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2025-12-31 | Powered by Claude AI